Qiang Fu1, Longxing Cao1, Huang Li2, Binghui Wang3, Zhiliang Li4. 1. Cardiovascular Division, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510280, China. 2. Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia. 3. Cardiovascular Division, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510280, China; Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia. 4. Cardiovascular Division, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510280, China. Email: lizhiliang020@126.com.
Abstract
OBJECTIVE: To review the current knowledge about the pathophysiological mechanisms, preclinical models, novel contributors and potential therapies of cardiorenal syndrome. DATA SOURCES: The literature concerning cardiorenal syndrome in this review was collected from PubMed published in English up to January 2014. STUDY SELECTION: Original articles and critical reviews related to cardiorenal syndrome were selected and carefully analyzed. RESULTS: Cardiorenal syndrome is a condition characterized by kidney and heart failure where failure of one organ worsens the function of the other thus further accelerating the progressive failure of both organs. The pathophysiology of cardiorenal syndrome is not fully understood, but may be caused by a complex combination of neurohormonal system activation, endothelial dysfunction, proteinuria, oxidative stress, uremic toxins and other factors. Managing cardiorenal syndrome is still a major therapeutic challenge in clinical practice because many of the drugs used to control heart failure can worsen renal function, and vice versa. Non-dialyzable uremic toxins, such as indoxyl sulfate, causing detrimental effects on the heart and kidney as well as stimulation of inflammatory responses, may be an effective therapeutic target for cardiorenal syndrome. CONCLUSIONS: Suitable disease models of cardiorenal syndrome are urgently needed to investigate the pathophysiology and effective therapeutic approaches to the condition. Non-dialyzable protein-bound uremic toxins that may have cardiac and renal effects may provide therapeutic benefit to cardiorenal syndrome patients.
OBJECTIVE: To review the current knowledge about the pathophysiological mechanisms, preclinical models, novel contributors and potential therapies of cardiorenal syndrome. DATA SOURCES: The literature concerning cardiorenal syndrome in this review was collected from PubMed published in English up to January 2014. STUDY SELECTION: Original articles and critical reviews related to cardiorenal syndrome were selected and carefully analyzed. RESULTS:Cardiorenal syndrome is a condition characterized by kidney and heart failure where failure of one organ worsens the function of the other thus further accelerating the progressive failure of both organs. The pathophysiology of cardiorenal syndrome is not fully understood, but may be caused by a complex combination of neurohormonal system activation, endothelial dysfunction, proteinuria, oxidative stress, uremic toxins and other factors. Managing cardiorenal syndrome is still a major therapeutic challenge in clinical practice because many of the drugs used to control heart failure can worsen renal function, and vice versa. Non-dialyzable uremic toxins, such as indoxyl sulfate, causing detrimental effects on the heart and kidney as well as stimulation of inflammatory responses, may be an effective therapeutic target for cardiorenal syndrome. CONCLUSIONS: Suitable disease models of cardiorenal syndrome are urgently needed to investigate the pathophysiology and effective therapeutic approaches to the condition. Non-dialyzable protein-bound uremic toxins that may have cardiac and renal effects may provide therapeutic benefit to cardiorenal syndromepatients.
Authors: Tobias Feldreich; Christoph Nowak; Tove Fall; Axel C Carlsson; Juan-Jesus Carrero; Jonas Ripsweden; Abdul Rashid Qureshi; Olof Heimbürger; Peter Barany; Peter Stenvinkel; Nicolas Vuilleumier; Philip A Kalra; Darren Green; Johan Ärnlöv Journal: J Nephrol Date: 2018-11-29 Impact factor: 3.902
Authors: Aleksandra Gąsecka; Łukasz Rzepa; Michał Konwerski; Magdalena Zawadzka; Karol Wysocki; Monika Budnik; Paweł Czub; Radosław Wilimski; Mateusz Wondołkowski; Joanna Wilczyńska-Burlikowska; Piotr Scisło; Marek Konop; Zenon Huczek; Janusz Kochman; Janusz Kochanowski; Grzegorz Opolski; Krzysztof J Filipiak; Marcin Ufnal; Agnieszka Kapłon-Cieślicka Journal: Cardiol J Date: 2022-04-26 Impact factor: 3.487